Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church and patents from Partners Healthcare-MGH's J. Keith Joung.
UpGuard's CSTAR Score ranges from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.
Book a call with one of our specialists and we'll arrange a time for a demo.